HALO - Company ID 0001159036
The table below shows HALOZYME THERAPEUTICS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.25M | $660.12M | $443.31M | $267.59M |
| Cost of revenue | $228.77M | $159.42M | $192.36M | $139.30M | $81.41M | $43.37M |
| Gross profit | - | - | - | - | - | - |
| R&D | - | $79.05M | $76.36M | $66.61M | $35.67M | $34.24M |
HALOZYME THERAPEUTICS, INC. reported annual revenue of $1.40B for fiscal year 2025. That is up 37.6% from $1.02B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $146.69M (FY 2016) to $1.40B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $207.09M |
| $154.34M |
| $149.18M |
| $143.53M |
| $50.32M |
| $45.74M |
| Operating income | $469.01M | $551.48M | $337.57M | $267.53M | $275.90M | $144.25M |
| Income tax | $149.99M | $113.04M | $66.73M | $46.79M | -$154.19M | $217.00K |
| Net income | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M | $129.09M |
| EPS (diluted) | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 |